Skip to content

Accelerated Stress CMR in Coronary Artery Disease

Accelerated Cardiovascular Magnetic Resonance in Coronary Artery Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05221762
Enrollment
167
Registered
2022-02-03
Start date
2021-07-01
Completion date
2025-11-30
Last updated
2025-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

This study will evaluate the diagnostic performance of an accelerated stress CMR protocol, comparing it with that of standard CMR assessment.

Detailed description

This is a prospective, single-centre diagnostic accuracy study comparing the diagnostic performance of (1) accelerated and (2) standard adenosine stress CMR scans in 167 patients with suspected coronary artery disease referred for invasive coronary angiography (which will serve as the reference standard - invasive FFR). The accelerated scan comprises accelerated cine and gadolinium imaging, with a standard stress scan (0.075mmol/kg gadolinium contrast). Subjects will undergo both scans pre-angiography (in randomised order), enabling a head-to-head comparison of diagnostic performance (diagnostic accuracy, sensitivity and specificity) for identifying functionally significant coronary disease (as defined by fractional flow reserve \<0.80). Objectives The primary objective is to determine, in patients with suspected angina, whether the accelerated CMR protocol achieves favourable diagnostic accuracy, using invasive FFR as the reference standard, and also compared with standard CMR assessment. Secondary objectives include comparing diagnostic performance of the accelerated CMR protocol with that of CT-FFR, a comparison of scan duration (overall and for each component - for standard and accelerated CMR), and patient tolerability and experience for each protocol (accelerated CMR, standard CMR and CTCA), as determined by a self-administered questionnaire rating patient comfort, symptoms experienced and perceived scan duration. Data analysis * Imaging data will be interpreted using the 16-segment American Heart Association (AHA) segmentation model * For visual assessment of perfusion, images will be analysed by two experienced cardiologists, acting independently (differences resolved by consensus). * For qualitative analysis, perfusion data will be analysed concurrently with late gadolinium images, with inducible ischaemia determined by the presence of a perfusion defect exceeding the area of scar. * For quantitative analysis, myocardial blood flow (MBF) will be quantified using inline Gadgetron data (flow maps providing segmental flows). * For qualitative analysis, ischaemia is defined as reversible hypoperfusion in two adjacent segments \[32-segment model\] exceeding the region of scar \[if present\], and for quantitative analysis, using a MBF threshold of 1.9ml/min/g.

Interventions

Cardiovascular magnetic resonance (CMR) at 3 Tesla

Sponsors

University of Glasgow
CollaboratorOTHER
Imperial College Healthcare NHS Trust
CollaboratorOTHER
University of Leicester
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged ≥18 years * Referred for invasive coronary angiography for investigation of chest pain * Willing and able to give informed consent * Willing and able (in the Investigators opinion) to comply with all study requirements. * Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study. * Able to understand written English

Exclusion criteria

* Recent acute coronary syndrome (\< 6 months) * Severe claustrophobia * Absolute contraindications to CMR - those with MR conditional or safe devices will be included * Second-/third-degree atrioventricular block * Severe chronic obstructive pulmonary disease * Moderate-severe asthma * Estimated glomerular filtration rate \<30 ml/min/1.73m2 * Women who are pregnant, breast-feeding or of child-bearing potential (premenopausal women) * Contraindication to iodinated contrast * Participants who have participated in a research study involving an investigational product in the past 12 weeks * Patients unable to understand written English

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of accelerated CMR (qualitative assessment)6 weeksPer vessel diagnostic accuracy of the accelerated CMR protocol (with qualitative perfusion assessment) and standard CMR protocol versus invasive coronary angiography with fractional flow reserve.
Diagnostic performance of accelerated CMR (quantitative assessment)6 weeksPer vessel diagnostic accuracy of the accelerated CMR protocol (with quantitative perfusion assessment) and standard CMR protocol versus invasive coronary angiography with fractional flow reserve.

Secondary

MeasureTime frameDescription
Sensitivity of accelerated CMR (patient level)6 weeksPer patient sensitivity of the accelerated protocol versus invasive coronary angiography with fractional flow reserve. This comparison will comprise two separate assessments of sensitivity against the reference standard - (1) algorithm with qualitative perfusion assessment (2) algorithm with quantitative perfusion assessment
Specificity of accelerated CMR (patient level)6 weeksPer patient specificity of the accelerated protocol versus invasive coronary angiography with fractional flow reserve. This comparison will comprise two separate assessments of specificity against the reference standard - (1) algorithm with qualitative perfusion assessment (2) algorithm with quantitative perfusion assessment
Diagnostic performance of accelerated CMR versus CTCA/FFRCT (1)6 weeksPer patient diagnostic accuracy of the accelerated CMR protocol (with qualitative perfusion assessment) for functionally significant coronary artery disease \[CAD\] (per patient level), compared with the diagnostic accuracy of CTCA/FFRCT.
Diagnostic performance of accelerated CMR versus CTCA/FFRCT (2)6 weeksPer patient diagnostic accuracy of the accelerated CMR protocol (with quantitative perfusion assessment) for functionally significant CAD (per patient level), compared with the diagnostic accuracy of CTCA/FFRCT.
Diagnostic performance of accelerated CMR versus computed tomography coronary angiography with computed tomography-derived fractional flow reserve (CTCA/FFRCT) (2)6 weeksPer patient diagnostic accuracy of the accelerated CMR protocol (with quantitative perfusion assessment) for functionally significant CAD (per patient level), compared with the diagnostic accuracy of CTCA/FFRCT.
Utility of rest perfusion assessment (1)6 weeksDiagnostic accuracy (per vessel and per patient levels) for functionally significant coronary artery disease with a stress-only protocol compared with the stress/rest protocol
Sensitivity of accelerated CMR (vessel level)6 weeksPer vessel sensitivity of the accelerated protocol versus invasive coronary angiography with fractional flow reserve. This comparison will comprise two separate assessments of sensitivity against the reference standard - (1) algorithm with qualitative perfusion assessment (2) algorithm with quantitative perfusion assessment
Utility of rest perfusion assessment (3)6 weeksSpecificity (per vessel and per patient levels) for functionally significant coronary artery disease with a stress-only protocol compared with the stress/rest protocol
Subjective experience1 weekComparison of patient tolerability and experience for each protocol (accelerated CMR, standard CMR and CTCA), as determined by a self-administered questionnaire rating patient comfort, symptoms experienced and perceived scan duration: 4 point scale \[1-4 with higher scores meaning worse outcome\].
Time duration of each scan/scan component.1 weekComparison of the time duration of each scan component (accelerated versus standard CMR versus CT protocols).
Image quality1 weekImage quality of each scan/scan component, assessed visually on a 4-point score - excellent (3), good (2), moderate (1) and poor (0).
Cost analysis2 yearsA cost consequence and budget impact analysis will be carried out, quantifying the effects of introducing the different diagnostic strategies into the current clinical pathway. Intervention costs and associated healthcare costs will be estimated for each testing strategy. Data on resource use such as staff time, scan duration and hospital days will be collected during the study period. Relevant unit costs will be applied to estimate the total costs. Generalised linear models will be used to analyse the data with adjustments that complement the secondary analyses (above), while accounting for the nature of skewed data. Uncertainty will be estimated by calculating 95% confidence intervals through non-parametric bootstrapping. Scenario-based sensitivity analyses will also be performed and threshold analyses to characterise uncertainty.
Utility of rest perfusion assessment (2)6 weeksSensitivity (per vessel and per patient levels) for functionally significant coronary artery disease with a stress-only protocol compared with the stress/rest protocol
Specificity of accelerated CMR (vessel level)6 weeksPer vessel specificity of the accelerated protocol versus invasive coronary angiography with fractional flow reserve. This comparison will comprise two separate assessments of specificity against the reference standard - (1) algorithm with qualitative perfusion assessment (2) algorithm with quantitative perfusion assessment

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026